NASDAQ:SYRS • US87184Q2066
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for SYROS PHARMACEUTICALS INC (SYRS).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-11-13 | TD Cowen | Downgrade | Buy -> Hold |
| 2024-11-13 | Brookline Capital | Downgrade | Buy -> Hold |
| 2024-11-13 | JMP Securities | Downgrade | Market Outperform -> Market Perform |
| 2024-11-13 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2024-11-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-13 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2024-08-13 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2024-08-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-08-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-03 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2024-04-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-10-03 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-08-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-11 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2023-05-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-03-03 | Oppenheimer | Maintains | Outperform |
| 2023-03-03 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-01-05 | Piper Sandler | Maintains | Overweight |
| 2022-11-15 | JMP Securities | Maintains | Market Outperform |
| 2022-11-15 | Oppenheimer | Maintains | Outperform |
| 2022-11-15 | HC Wainwright & Co. | Maintains | Buy |
| 2022-08-10 | Oppenheimer | Maintains | Outperform |
| 2022-07-12 | HC Wainwright & Co. | Maintains | Buy |
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 23.49M 55.67% | 14.88M -36.65% | 9.936M -33.23% | -100.00% | 1.7M | 1.7M | -100.00% | 5.1M | 5.1M | ||||
| EBITDA YoY % growth | -96.4M -21.63% | -123.39M -28.00% | -124.247M -0.69% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -99.42M -20.80% | -126.36M -27.10% | -126.499M -0.11% | -112.098M 11.38% | -41.412M 63.06% | -35.7M 13.79% | -101.864M -185.33% | -49.98M 50.93% | -57.12M -14.29% | -64.26M -12.50% | -130.764M -103.49% | -134.64M -2.96% | |
| Operating Margin | -423.24% | -849.19% | -1,273.14% | N/A | N/A | -2,100.00% | -5,992.00% | N/A | N/A | N/A | -2,564.00% | -2,640.00% | |
| EPS YoY % growth | -13.80 24.18% | -12.78 7.39% | -5.76 54.93% | -1.53 73.44% | -0.97 36.67% | -0.61 36.84% | -3.13 -411.67% | -3.42 -9.28% | -4.23 -23.55% | -2.75 34.86% | -2.38 13.70% | -2.42 -1.72% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.66 69.59% | -0.39 -287.60% | -0.49 17.02% | -0.45 -180.50% | -0.43 34.62% |
| Revenue Q2Q % growth | -100.00% | ||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -25.908M 4.06% | -15.402M 50.19% | -19.635M 28.38% | -18.411M 29.68% | -18.666M 27.95% |
All data in USD
9 analysts have analysed SYRS and the average price target is 10.71 USD. This implies a price increase of 9038.23% is expected in the next year compared to the current price of 0.1172.
SYROS PHARMACEUTICALS INC (SYRS) will report earnings on 2025-05-12, before the market open.
The consensus EPS estimate for the next earnings of SYROS PHARMACEUTICALS INC (SYRS) is -0.66 USD and the consensus revenue estimate is 0 USD.
The expected long term growth rate for SYROS PHARMACEUTICALS INC (SYRS) is -47.5%.